Drawing for Serial No. 79285191

USPTO serial 79285191

Serial No. 79285191

Reviewed by CopyMark Law Group

Reg. 6197733Status 700Renewal
Filing date
Status date
Registration date
Nov 17, 2020
Examiner
SCLEIDOROVICH, JOANNA YAEL
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 79285191?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRIVERALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 17, 2025REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Aug 28, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 14, 2021FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 24, 2021FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 24, 2021FIMPFINAL DISPOSITION PROCESSED—
Feb 17, 2021FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Feb 12, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 17, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 1, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 1, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 12, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 27, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 24, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 23, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 23, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 22, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 22, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 22, 2020ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 22, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 22, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 22, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 18, 2020RFNTREFUSAL PROCESSED BY IB—
Jun 28, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 28, 2020RFRRREFUSAL PROCESSED BY MPU—
May 29, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 28, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 27, 2020DOCKASSIGNED TO EXAMINER—
May 26, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
May 21, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 20, 2020LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
May 14, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance